Cochlear (COH.AX) Stock Price
Cochlear Price
Over the last 19 years Cochlear grew revenue by 9.0% annually, reaching 2.34 B AUD. Earnings per share have grown at 7.7% per year over the last 19 years. For Cochlear, the net margin of 16.6% is down versus 21.8% a few years ago. At today's price the dividend yield works out to roughly 4.35%. The payout ratio is around 98% of earnings. The dividend has grown at 7.7% per year over the past 19 years. The consensus 12-month price target for Cochlear is 252.40 AUD, about 88.8% above where the stock trades today. Of 19 analysts, 8 rate the stock a buy — an overall Hold consensus. The stock trades about 49% above its 52-week low.
Cochlear stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cochlear over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cochlear stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cochlear's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cochlear Price |
|---|---|
| 9/1/2026 | 133.69 AUD |
| 8/31/2026 | 134.18 AUD |
| 8/28/2026 | 136.34 AUD |
| 8/27/2026 | 134.94 AUD |
| 8/26/2026 | 137.71 AUD |
| 8/25/2026 | 137.67 AUD |
| 8/24/2026 | 135.62 AUD |
| 8/21/2026 | 135.82 AUD |
| 8/20/2026 | 138.65 AUD |
| 8/19/2026 | 137.30 AUD |
| 8/18/2026 | 141.20 AUD |
| 8/17/2026 | 132.73 AUD |
| 8/14/2026 | 133.60 AUD |
| 8/13/2026 | 133.93 AUD |
| 8/12/2026 | 131.68 AUD |
| 8/11/2026 | 129.27 AUD |
| 8/10/2026 | 126.73 AUD |
| 8/7/2026 | 124.86 AUD |
| 8/6/2026 | 125.63 AUD |
| 8/5/2026 | 122.00 AUD |
| 8/4/2026 | 122.32 AUD |
| 8/3/2026 | 120.13 AUD |
| 7/31/2026 | 119.94 AUD |
| 7/30/2026 | 122.20 AUD |
| 7/29/2026 | 122.50 AUD |
| 7/28/2026 | 119.88 AUD |
| 7/27/2026 | 114.86 AUD |
| 7/24/2026 | 111.61 AUD |
| 7/23/2026 | 112.11 AUD |
| 7/22/2026 | 112.19 AUD |
Cochlear Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.AUD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 | 1.25 | 1.36 | 1.43 | 1.32 | 1.50 | 1.65 | 1.94 | 2.24 | 2.34 | 2.33 | 2.38 | 2.53 | 2.69 | 3.08 | 3.55 |
| 22.16 | 10.88 | 8.78 | 4.62 | -7.43 | 13.41 | 10.09 | 17.48 | 15.44 | 4.83 | -0.43 | 2.10 | 6.09 | 6.61 | 14.14 | 15.54 |
| 71.95 | 71.99 | 73.73 | 75.88 | 74.55 | 73.35 | 75.85 | 74.79 | 74.85 | 73.71 | 73.71 | 73.71 | 73.71 | 73.71 | 73.71 | 73.71 |
| 0.81 | 0.90 | 1.01 | 1.08 | 0.98 | 1.10 | 1.25 | 1.45 | 1.67 | 1.73 | 1.72 | 1.76 | 1.86 | 1.99 | 2.27 | 2.62 |
| 270.00 | 324.00 | 348.00 | 359.00 | 241.00 | 355.00 | 394.00 | 406.00 | 509.00 | 522.00 | 415.00 | 471.00 | 513.00 | 576.00 | 667.00 | – |
| 23.89 | 25.86 | 25.53 | 25.18 | 18.26 | 23.71 | 23.91 | 20.97 | 22.77 | 22.28 | 17.79 | 19.77 | 20.30 | 21.38 | 21.69 | – |
| 188.00 | 223.00 | 245.00 | 276.00 | -238.00 | 326.00 | 289.00 | 300.00 | 356.00 | 388.00 | 309.00 | 342.00 | 379.00 | 423.00 | 487.00 | 685.00 |
| 29.66 | 18.62 | 9.87 | 12.65 | -186.23 | -236.97 | -11.35 | 3.81 | 18.67 | 8.99 | -20.36 | 10.68 | 10.82 | 11.61 | 15.13 | 40.66 |
| 3.29 | 3.86 | 4.29 | 4.71 | 2.29 | 2.30 | 3.25 | 4.06 | 5.42 | 5.82 | 5.87 | 6.11 | 6.36 | – | – | – |
| 33.74 | 17.33 | 11.14 | 9.79 | -51.38 | 0.44 | 41.30 | 24.92 | 33.50 | 7.38 | 0.86 | 4.09 | 4.09 | – | – | – |
| 57.24 | 57.47 | 57.60 | 57.71 | 59.63 | 65.73 | 65.77 | 65.90 | 65.72 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cochlear generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cochlear retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cochlear's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cochlear has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cochlear's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cochlear stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear business model & stock analysis
Cochlear SWOT Analysis
Strengths
Cochlear Ltd possesses several key strengths that contribute to its success in the market. Firstly, the company is a pioneer and leader in the field of implantable hearing solutions, with over 30 years of experience. This enables them to offer innovative and technologically advanced products that provide significant benefits to individuals with hearing loss.
Moreover, Cochlear has established a strong global presence with a wide distribution network spanning across more than 100 countries. This allows them to reach a large customer base and maintain strong relationships with healthcare professionals, ensuring accessibility and support for their products. Additionally, the company has a robust intellectual property portfolio, providing them with a competitive advantage in the market.
Weaknesses
Despite its strengths, Cochlear Ltd faces a few weaknesses that could pose challenges. One significant weakness is the high cost associated with their implantable hearing solutions. This can limit their accessibility to a substantial portion of the population, particularly in developing countries or regions where healthcare budgets are constrained.
Another weakness lies in the complexity of the surgical procedure required for implanting their hearing devices. This could deter potential customers who might prefer less invasive options or who are reluctant to undergo surgery. Additionally, as a specialized medical device company, Cochlear relies heavily on regulatory approvals, which can lead to delays in product launches and market entry.
Opportunities
Cochlear Ltd operates in an industry with several significant opportunities. Firstly, the growing global prevalence of hearing loss, coupled with an aging population, presents a substantial market opportunity for the company. They can leverage their expertise and portfolio to address the unmet needs of individuals with hearing impairment worldwide.
Furthermore, advancements in technology and digital healthcare offer opportunities for Cochlear to develop innovative solutions that improve user experience and convenience. The increasing adoption of telehealth and remote patient monitoring also opens new avenues for Cochlear to provide virtual support and services to its customers, enhancing accessibility and convenience.
Threats
Cochlear Ltd operates in a competitive market with several threats that could impact its business. One significant threat is the presence of well-established competitors in the hearing solutions industry who have the financial resources and R&D capabilities to develop competitive products. This intensifies the need for Cochlear to maintain its focus on innovation and differentiation.
Additionally, changes in healthcare policies and reimbursement systems can pose a threat to Cochlear's financial performance. Reimbursement cuts or changes in coverage policies may affect the affordability and accessibility of the company's products, impacting market demand. Lastly, economic downturns or financial crises can also have an adverse effect on Cochlear's business, as discretionary healthcare spending may decline during such periods.
Cochlear Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Cochlear historical P/E ratio, EBIT multiple, and P/S ratio
Cochlear annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cochlear shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Dividend History
31 years of dividend payments · 5 consecutive increases
Cochlear dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Cochlear forecasts and price targets in September 2026
Analyst Price Targets 2026Cochlear Earnings Calls
Cochlear Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 2/16/2024 | 2.60AUD | - | 1.04 BAUD | - | 2024 Q2 |
| 8/17/2023 | 2.57AUD | - | 960.50 MAUD | - | 2023 Q4 |
| 2/20/2023 | 1.92AUD | - | 870.52 MAUD | - | 2023 Q2 |
| 8/19/2022 | 1.94AUD | - | 846.25 MAUD | - | 2022 Q4 |
| 2/22/2022 | 1.99AUD | - | 796.42 MAUD | - | 2022 Q2 |
| 8/20/2021 | 1.79AUD | - | 733.62 MAUD | - | 2021 Q4 |
| 2/19/2021 | 1.46AUD | - | 680.43 MAUD | - | 2021 Q2 |
| 8/18/2020 | 0.36AUD | - | 518.33 MAUD | - | 2020 Q4 |
| 2/18/2020 | 2.53AUD | - | 806.91 MAUD | - | 2020 Q2 |
| 8/16/2019 | 2.47AUD | - | 774.48 MAUD | - | 2019 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Cochlear stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Cochlear shareholder structure
| % | Name |
|---|---|
6.18765% | |
5.99021% | |
4.86832% | |
2.02943% | |
1.76145% | |
1.56275% |
Cochlear Beneficial Ownership Filings (SEC 13D/G)
Cochlear Executives and Management Board
21 members · avg. age 61 · 43 % women
Mr. Diggory Howitt (56)
President, Chief Executive Officer, Executive Director
5.08 M AUD
Management
Mr. Jan Janssen
Chief Technology Officer
Mr. Stuart Sayers
President, Asia Pacific & Latin America
Mr. Anthony Bishop
President - EMEA
Ms. Lisa Aubert
President - North America
Ms. Sarah Thom
Chief Financial Officer
Mr. Dean Phizacklea
Senior Vice President - Global Strategic Marketing
Board of Directors
Ms. Alison Deans (57)
Non-Executive Independent Chairman of the Board
Mr. Michael Del Prado (61)
Non-Executive Independent Director
Ms. Karen Penrose
Non-Executive Director
Sir Michael Daniell (67)
Non-Executive Director
Mr. Glen Boreham (59)
Non-Executive Independent Director
Ms. Christine Mcloughlin
Non-Executive Independent Director
Frequently asked questions about Cochlear
Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.
Cochlear Ltd is primarily active in the healthcare and medical device industries.
The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.
Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.
Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.
Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.
Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.
Analysts currently set an average price target of 265.71 AUD for the Cochlear stock (median: 252.40 AUD), implying +98.7 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Cochlear stock: 9 recommend buying, 9 holding and 1 selling. For 2026, analysts expect Cochlear to generate revenue of 2.33 B AUD and earnings per share of 4.72 AUD.
Converted at the current exchange rate, the Cochlear share trades at 82.51 EUR (133.69 AUD).
The Cochlear share (COH.AX) is listed on 7 stock exchanges, including: Frankfurt (OC5.F), München (OC5.MU), Düsseldorf (OC5.DU), Hamburg (OC5.HM), SIX (Zürich) (COH.SW), ASX (COH.AX).
Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.
The expected revenue of Cochlear is 2.33 B AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cochlear is 309.97 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cochlear is currently 28.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cochlear stock.
The price-to-sales ratio (P/S) of Cochlear is currently 3.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cochlear stock.
The Eulerpool Quality Score for Cochlear is 7/10.
The ISIN of Cochlear is AU000000COH5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cochlear is 898321. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cochlear is COH.AX. The ticker symbol is used to trade Cochlear shares on the stock exchange.
Over the past 12 months, Cochlear paid a dividend of 5.82 AUD . This corresponds to a dividend yield of about 4.35 %. For the coming 12 months, Cochlear is expected to pay a dividend of 6.11 AUD.
The current dividend yield of Cochlear is 4.35 %.
Cochlear pays a dividend, distributed in the months of , , , .
Cochlear paid dividends every year for the past 30 years.
For the upcoming 12 months, dividends amounting to 6.11 AUD are expected. This corresponds to a dividend yield of 4.57 %.
Cochlear is assigned to the 'Health' sector.
To receive the latest dividend of Cochlear from amounting to 2.93 AUD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Cochlear distributed 4.88 AUD as dividends.
The dividends of Cochlear are distributed in AUD.
Cochlear stock
Cochlear Peer Group
Cochlear Ticker
Cochlear FIGI
All fundamentals and in-depth analysis of Cochlear
Our stock analysis for Cochlear stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cochlear. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.